摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Phenyl-isoxazol-5-yl-(3-piperidin-1-yl-propyl)-amine | 86684-07-3

中文名称
——
中文别名
——
英文名称
3-Phenyl-isoxazol-5-yl-(3-piperidin-1-yl-propyl)-amine
英文别名
3-Phenyl-isoxazol-5-yl-(3-piperidin-1-yl-propyl)amine;3-phenyl-N-(3-piperidin-1-ylpropyl)-1,2-oxazol-5-amine
3-Phenyl-isoxazol-5-yl-(3-piperidin-1-yl-propyl)-amine化学式
CAS
86684-07-3
化学式
C17H23N3O
mdl
——
分子量
285.389
InChiKey
CPRZHPQMZSXFCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    21
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    41.3
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    3-氯苄溴3-Phenyl-isoxazol-5-yl-(3-piperidin-1-yl-propyl)-amine 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 (3-Chloro-benzyl)-(3-phenyl-isoxazol-5-yl)-(3-piperidin-1-yl-propyl)-amine
    参考文献:
    名称:
    Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)
    摘要:
    The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50S of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min. (C) 2002 Published by Elsevier Science Ltd.
    DOI:
    10.1016/s0960-894x(01)00745-4
  • 作为产物:
    参考文献:
    名称:
    Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)
    摘要:
    The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50S of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min. (C) 2002 Published by Elsevier Science Ltd.
    DOI:
    10.1016/s0960-894x(01)00745-4
点击查看最新优质反应信息

文献信息

  • Thrombin receptor antagonists
    申请人:Merck & Co., Inc.
    公开号:US06544982B1
    公开(公告)日:2003-04-08
    A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    一种具有以下公式的凝血酶受体拮抗剂,用于抑制血小板聚集。这些化合物可用于作用于凝血酶受体的方法,包括向哺乳动物,最好是人类,投与治疗有效但非毒性量的该化合物。
  • US6544982B1
    申请人:——
    公开号:US6544982B1
    公开(公告)日:2003-04-08
  • Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)
    作者:Philippe G Nantermet、James C Barrow、George F Lundell、Janetta M Pellicore、Kenneth E Rittle、MaryBeth Young、Roger M Freidinger、Thomas M Connolly、Cindra Condra、Jerzy Karczewski、Rodney A Bednar、Stanley L Gaul、Robert J Gould、Kris Prendergast、Harold G Selnick
    DOI:10.1016/s0960-894x(01)00745-4
    日期:2002.2
    The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50S of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min. (C) 2002 Published by Elsevier Science Ltd.
查看更多